Sascha d'Almeida, Sinisa Markovic, Patrick Hermann, Hendrik Bracht, Johannes Peifer, Thomas J Ettrich, Armin Imhof, Shaoxia Zhou, Manfred Weiss, Andreas Viardot, Wolfgang Rottbauer, Tillman Dahme
Cases of thromboembolic events in 2021 flared up the discussion about the safety of Astra Zeneca's AZD1222 vaccine. We hereby report three cases of pulmonary embolism (PE), one case of extended portal vein thrombosis, and one case of combined portal vein thrombosis and PE within 2 weeks after vaccination with the Astra Zeneca AZD1222 vaccine in a 60-year-old, a 50-year old, a 33-year-old, a 30-year old, and a 40-year-old male in that year. All patients were healthy before. In three patients, we observed thrombocytopenia and to some extent unusually low antibody levels for the Spike Protein (S-protein), while the other two had normal thrombocyte counts...
August 1, 2023: Human Vaccines & Immunotherapeutics